Joint Research and Development of a Drug-Coated PTA Balloon Catheter
First written in FY2016. 2 of 3 entries say "Dropped", first in FY2017-Q3. Latest entry: FY2017.
1 other company's latest entry also says "Dropped".
- FY2017DroppedAnnual report
「The company obtained the CE mark in fiscal 2016 for Mongoose, a narrow 3.3-Fr catheter for which expansion into the United States began in fiscal 2016. Including MeitoMasamune, which has already obtained the CE mark, the company will expand exports and further expand its sales network for catheters used in percutaneous coronary intervention (PCI) to major European facilities. In addition, the joint research and development project for a drug-coated PTA balloon catheter (NF-κB decoy oligo coating), intended to prevent vascular restenosis and pursued as a new initiative to develop next-generation medical devices by our group, アンジェスＭＧ株式会社 and HOSOKAWA MICRON CORPORATION, was terminated after the results of the clinical trial begun in September 2012 were reviewed and no statistically significant difference in efficacy from existing PTA balloon catheters was obtained, following discussions among the parties.」
The annual report explicitly states that the joint development agreement was terminated because the clinical trial analysis found no statistically significant difference in efficacy from existing products. - FY2017-Q3DroppedAnnual report
「On 6 December 2016, our company and アンジェスＭＧ株式会社 agreed to terminate the joint development agreement for the NF-κB decoy oligo-coated PTA balloon catheter.」
The filing states that an agreement was reached to terminate the joint development agreement with アンジェスＭＧ株式会社 for the drug-coated PTA balloon catheter. - FY2016First statedAnnual report
「As a new initiative to develop next-generation medical devices, our group is conducting joint research and development with アンジェスＭＧ株式会社 and HOSOKAWA MICRON CORPORATION on a drug-coated PTA balloon catheter (NF-κB decoy oligo coating) intended to prevent vascular restenosis.」
The company has identified a next-generation medical device intended to prevent restenosis as a joint research and development project with 2 external companies.